Akero Therapeutics Inc
AKRO54.140USD
+0.100+0.19%
收盘 11/10, 16:00（美东）报价延迟15分钟
4.34B总市值
亏损市盈率 TTM
关于 Akero Therapeutics Inc 公司
Akero Therapeutics, Inc. 是一家临床阶段公司。该公司正在为患有严重代谢疾病且医疗需求尚未得到满足的患者开发转化疗法，包括代谢功能障碍相关脂肪性肝炎 (MASH)，这是一种尚无任何获批疗法的疾病。Efruxifermin (EFX) 是其用于治疗 MASH 的主要候选产品，目前正在进行 IIb 期 SYMMETRY、III 期 SYNCHRONY 组织学和 III 期 SYNCHRONY 真实世界研究中进行评估。III 期 SYNCHRONY 计划以两项 IIb 期临床试验的结果为基础，即针对肝硬化前期 MASH 患者的 HARMONY 研究和针对 MASH 导致的肝硬化患者的 SYMMETRY 研究。EFX 是成纤维细胞生长因子 21 (FGF21) 的类似物，FGF21 是一种内源性表达的激素，可防止细胞应激并调节全身脂质、碳水化合物和蛋白质的代谢。 EFX 旨在提供方便的每周一次剂量。
Akero Therapeutics Inc简介
公司代码AKRO
公司名称Akero Therapeutics Inc
上市日期Jun 20, 2019
CEODr. Andrew Cheng, M.D., Ph.D.
员工数量63
证券类型Ordinary Share
年结日Jun 20
公司地址601 Gateway Boulevard, Suite 350
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94080
电话16504876488
网址https://akerotx.com/
公司代码AKRO
上市日期Jun 20, 2019
CEODr. Andrew Cheng, M.D., Ph.D.
Akero Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
393.38K
+51.69%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
217.63K
+13.41%
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
35.53K
+30.32%
Mr. Patrick Lamy
Mr. Patrick Lamy
Senior Vice President - Commercial Strategy
Senior Vice President - Commercial Strategy
32.93K
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Yuan Xu, Ph.D.
Dr. Yuan Xu, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Graham L. Walmsley, M.D., Ph.D.
Dr. Graham L. Walmsley, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott A. Gangloff
Mr. Scott A. Gangloff
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Judy Chou, Ph.D.
Dr. Judy Chou, Ph.D.
Independent Director
Independent Director
--
--
Dr. Seth L. Harrison, M.D.
Dr. Seth L. Harrison, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
393.38K
+51.69%
Dr. Jonathan Young, J.D., Ph.D.
Dr. Jonathan Young, J.D., Ph.D.
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
217.63K
+13.41%
Ms. Catriona Yale
Ms. Catriona Yale
Chief Development Officer
Chief Development Officer
35.53K
+30.32%
Mr. Patrick Lamy
Mr. Patrick Lamy
Senior Vice President - Commercial Strategy
Senior Vice President - Commercial Strategy
32.93K
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Yuan Xu, Ph.D.
Dr. Yuan Xu, Ph.D.
Independent Director
Independent Director
--
-100.00%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 9月3日 周三
更新时间: 9月3日 周三
持股股东
股东类型
持股股东
持股股东
占比
Janus Henderson Investors
8.19%
General Atlantic LLC
6.97%
RTW Investments L.P.
6.65%
BlackRock Institutional Trust Company, N.A.
6.15%
The Vanguard Group, Inc.
5.48%
其他
66.56%
持股股东
持股股东
占比
Janus Henderson Investors
8.19%
General Atlantic LLC
6.97%
RTW Investments L.P.
6.65%
BlackRock Institutional Trust Company, N.A.
6.15%
The Vanguard Group, Inc.
5.48%
其他
66.56%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
47.16%
Investment Advisor
33.05%
Hedge Fund
22.49%
Private Equity
9.32%
Research Firm
3.22%
Venture Capital
3.01%
Individual Investor
1.29%
Foundation
0.41%
Pension Fund
0.32%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
509
95.38M
115.92%
-917.24K
2025Q2
491
87.62M
109.91%
-627.50K
2025Q1
495
89.01M
111.79%
+1.41M
2024Q4
453
76.50M
96.29%
-13.73M
2024Q3
445
77.37M
111.97%
-14.20M
2024Q2
428
76.12M
110.88%
-16.59M
2024Q1
421
77.80M
117.45%
+1.74M
2023Q4
401
63.49M
113.86%
-5.60M
2023Q3
387
61.40M
112.62%
-2.96M
2023Q2
363
60.44M
111.44%
+4.13M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Janus Henderson Investors
6.74M
8.42%
-330.09K
-4.67%
Jun 30, 2025
General Atlantic LLC
5.73M
7.17%
+500.00K
+9.55%
Jun 30, 2025
RTW Investments L.P.
5.48M
6.85%
-1.94M
-26.17%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.06M
6.33%
-421.07K
-7.68%
Jun 30, 2025
The Vanguard Group, Inc.
4.52M
5.65%
+297.51K
+7.05%
Jun 30, 2025
T. Rowe Price Associates, Inc.
4.42M
5.53%
-310.43K
-6.56%
Jun 30, 2025
Deep Track Capital LP
3.04M
3.8%
-167.67K
-5.22%
Jun 30, 2025
Avoro Capital Advisors LLC
3.50M
4.38%
+3.50M
--
Jun 30, 2025
Wellington Management Company, LLP
3.41M
4.26%
-2.53M
-42.56%
Jun 30, 2025
State Street Investment Management (US)
2.75M
3.43%
+250.82K
+10.05%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
Simplify Propel Opportunities ETF
10.44%
ALPS Medical Breakthroughs ETF
2.19%
SPDR S&P Biotech ETF
1.64%
AltShares Merger Arbitrage ETF
1.63%
Direxion Daily S&P Biotech Bull 3X Shares
0.86%
Virtus LifeSci Biotech Clinical Trials ETF
0.64%
Tema Heart & Health ETF
0.63%
ProShares Ultra Nasdaq Biotechnology
0.39%
Invesco Nasdaq Biotechnology ETF
0.38%
iShares Biotechnology ETF
0.32%
查看更多
Simplify Propel Opportunities ETF
占比10.44%
ALPS Medical Breakthroughs ETF
占比2.19%
SPDR S&P Biotech ETF
占比1.64%
AltShares Merger Arbitrage ETF
占比1.63%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.86%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.64%
Tema Heart & Health ETF
占比0.63%
ProShares Ultra Nasdaq Biotechnology
占比0.39%
Invesco Nasdaq Biotechnology ETF
占比0.38%
iShares Biotechnology ETF
占比0.32%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
